ClinicalTrials.gg
RecruitingNCT05846399CATBITEUpdated Oct 15, 2025

CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)

A Phase 4 interventional study of Amoxicillin/clavulanate and Ciprofloxacin in Cat Bite, Hand Injuries and Arm Injury, sponsored by University of Missouri-Columbia. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-15.

Sponsored by University of Missouri-Columbia · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Hand Injuries with a site in United States — 8 open to participants now, 8 under way, none of them phase 3. Hand Injuries · United States.

Planned enrollment
6th of 26
72 · median 30
Started
2023
with 2 others
Phase 4
2 of 27
1 open now
Registered
24th of 27
by date
Lead sponsor
2 of 27
University of Missouri-Columbia

Among the 27 studies in Hand Injuries with a site in United States, this one is the 6th largest by planned enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2023, is one of 2 in phase 4, and was the 24th registered.

Hand Injuries

122 studies on the registry are indexed under Hand Injuries; 35 are open to participants now.

Browse Hand Injuries studies →

Open to participants now

8 of the 27 studies in Hand Injuries with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Hand Injuries studies recruiting now, 14 (54%) set no upper age limit and 10 (38%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Hand Injuries with a site in United States, or all of them as a file.
02

Study summary

Cat bites are puncture wounds that have the potential to seed bacteria deep within the joint capsule, periosteum, and bone. The hand is the most common site of bite injuries. Pasteurella multocida is the is the most common organism isolated from the mouths of cats that can cause infections after a bite. Prophylactic antibiotics are often recommended with amoxicillin-clavulanate for 3-5 days to decrease the incidence of developing an infection. However, only one randomized controlled clinical trial consisting of 12 patients has been performed to justify this course of treatment, raising the possibility that the use of antibiotics could be reduced or even eliminated. Investigators will compare different durations of prophylactic antibiotics and a placebo control for cat bites to the hand/forearm presenting to the Emergency Department, Urgent Care, Plastic Surgery Clinic using a randomized, controlled, double-blind clinical trial. Participants presenting to the University of Missouri Hospital Emergency Department, Missouri University (MU) Healthcare Urgent Care, Plastic Surgery Clinic over the next year will be offered the chance to enroll if they meet the inclusion/exclusion criteria. For inclusion, participants will be >18 years of age, have cat bites to the hand or distal to elbow, and present within 24 hours of the cat bite injury. Participants must not present with active local or systemic infections, have received antibiotics within the past 30 days, or be immunocompromised (primary and secondary immunodeficiencies). Participants will be randomized to one of three treatment arms (placebo; amoxicillin-clavulanate 1 day; amoxicillin-clavulanate 5 days). Outcomes are the development of an infection at the location of the cat bite and/or systemic infection, adverse effects of interventions, disability assessed by Quick Disabilities of Arm, Shoulder and Hand (QuickDASH) scores, and quality of life (QOL) assessed by HAND Questionnaire (HAND-Q) scores. Infection will be assessed at day 0, day 2, day 7+/-2, day 14+/-2, and day 30+/-2 by vital signs, laboratory values, physical examination and with an infrared and digital camera. All measures will be within the standard of care, apart from the infrared camera, QuickDASH, and HAND-Q scores. The anatomic locations of cat bites to the hand/forearm will be assessed for correlations with infections.

Read the detailed description

Cat bites have been reported as the second most common domestic animal bite in the United States, ranging from 5%-15% of all bites. The hand is the most common site of bite injuries. Cat bites are puncture wounds that have the potential to seed bacteria deep within the joint capsule, periosteum and bone. As a result, infection is a serious complication, reported in 30%-50% of cat bites. The median time to signs and symptoms of infection following a cat bite is typically short (approximately 12 hours). Direct healthcare costs associated with management of cat and dog bites in the United States estimate >$850,000,000 annually and do not consider the indirect costs associated with time off work, rehabilitation, and permanent impairment.

The average cat bite wound culture yields five types of bacterial isolates. Mixed aerobic and anaerobic bacteria are observed in 60% of cases. Pasteurella multocida is the is the most common organism isolated from the mouths of cats that can cause infections after a bite. Pasteurella species are isolated from 75% of cat bite wounds, and the incubation period for Pasteurella infection is one to three days. Capnocytophaga canimorsus can cause bacteremia and fatal sepsis after animal bites, especially in patients with asplenia, alcoholism, or underlying hepatic disease. The incubation period for Capnocytophaga infection is one to three days. Bartonella henselae may be transmitted via the bite of an infected cat and contact with cat saliva via broken skin or mucosal surfaces. The incubation period for Bartonella infection is 7 to 14 days. Anaerobes isolated from dog and cat bite wounds include Bacteroides species, fusobacteria, Porphyromonas species, Prevotella species, cutibacteria (formerly propionibacteria), and peptostreptococci.

Prophylactic antibiotics are often recommended to decrease the incidence of developing an infection. Broad antibiotic coverage is recommended to address the polymicrobial nature of common oral flora and bite infections. Pasteurella species are generally susceptible to penicillin and ampicillin, but staphylococci and anaerobic species often produce beta-lactamase, which provides resistance to these antibiotics. Adding a beta-lactamase inhibitor significantly increases the effectiveness of these antibiotics, and amoxicillin-clavulanate is the oral antibiotic of choice for human, dog, and cat bites. Infectious Diseases Society of America (IDSA) guidelines recommend antibiotic prophylaxis with amoxicillin-clavulanate 875-125mg twice daily (BID) for 3-5 days or ciprofloxacin 500-750mg BID + clindamycin 300-450mg three times daily (TID) if a participant has a penicillin allergy. However, only one randomized controlled clinical trial (RCT) has been performed to date to assess the efficacy of prophylactic antibiotics following cat bites. Adult participants with uninfected full-thickness wounds presenting within 24 hours of injury to the emergency department were considered. Participants were randomly assigned to receive oxacillin 500mg four times daily (QID) for five days (n=5) or identically appearing placebo (n=6). Four of six participants receiving placebo, but none of the five participants receiving oxacillin, developed a wound infection (P = 0.045).

Immunocompetent adult participants presenting within 24 hours of a cat bite without any signs or symptoms of infection may benefit from advances in wound care alone or only need a maximum of 24 hours of antibiotic prophylaxis. Furthermore, a Cochrane review aggregating data from clinical trials from the literature concluded, "There is no evidence that the use of prophylactic antibiotics is effective for cat or dog bites." The investigators' hypothesis is that administration of 5 days of prophylactic antibiotics will not reduce the incidence of infection in participants evaluated and treated within 24 hours of cat bite injury, who do not exhibit signs of an active infection.

03

Conditions studied

  • Cat Bite
  • Hand Injuries
  • Arm Injury
  • Infection, Bacterial
  • Anti-bacterial Agents
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients greater or equal to 18 years of age.
  • Bitten by a cat.
  • Location of bite is the hand and/or forearm (distal to elbow).
  • Presenting \<24 hours following a cat bite to the hand/forearm.
  • English speaking

Exclusion criteria

Exclusion Criteria:

  • Patients who present with active local or systemic infections

    1. Purulent drainage from the cat bite
    2. Redness AND swelling at the location of the cat bite
  • Having a fever >100.4° F or >38° C)-Received antibiotics within the past 30 days
  • Received antibiotics within the past 30 days
  • Patients unwilling to take study medication
  • Patients unwilling to attend scheduled follow-up evaluations or complete study forms
  • Pregnant Women
  • Type I reaction to any of the study interventions
  • patients (primary and secondary immunodeficiencies) Primary
  • Lymphoproliferative Syndrome (ALPS)
  • Autoimmune Polyglandular Syndrome type 1 (APS-1)
  • B-cell Expansion with Nuclear factor kappa-light-chain-enhancer of activated B cells and T-cell Anergy (BENTA) Disease
  • Caspase Eight Deficiency State (CEDS)
  • Caspase Recruitment Domain Family Member 9 (CARD9) Deficiency and Other Syndromes of Susceptibility to Candidiasis
  • Cartilage-hair hypoplasia
  • Chédiak-Higashi syndrome
  • Chronic Granulomatous Disease (CGD)
  • Common Variable Immunodeficiency (CVID)
  • Complement Deficiencies
  • Congenital Neutropenia Syndromes
  • Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4) Deficiency
  • Cyclic neutropenia
  • DiGeorge syndrome
  • Dedicator Of Cytokinesis 8 (DOCK8) Deficiency
  • GATA-binding protein 2 (GATA2) Deficiency
  • Glycosylation Disorders with Immunodeficiency
  • Hyper-Immunoglobulin E Syndromes (HIES)
  • Hyper-Immunoglobulin M Syndromes
  • Interferon Gamma, Interleukin 12 and Interleukin 23 Deficiencies
  • Leukocyte Adhesion Deficiency (LAD) Types 1 and 2
  • Lipopolysaccharide Responsive Beige-Like Anchor Protein (LRBA) Deficiency
  • Phosphatidylinositol 3-kinase (PI3-Kinase) Disease
  • Phospholipase C gamma 2 (PLCG2) associated Antibody Deficiency and Immune Dysregulation (PLAID)
  • Severe Combined Immunodeficiency (SCID)
  • Selective Immunoglobulin A (IgA) deficiency
  • Signal transducer and activator of transcription 3 (STAT3) Dominant-Negative Disease
  • STAT3 Gain-of-Function Disease
  • Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
  • Wiskott-Aldrich Syndrome (WAS)
  • X-Linked Agammaglobulinemia (XLA)
  • X-Linked Lymphoproliferative Disease (XLP)
  • X-linked magnesium transporter 1 (MAGT1) deficiency with increased susceptibility to Epstein-Barr virus (EBV) infection and N-linked glycosylation defect (XMEN) Disease
  • Zeta-associated protein 70 (ZAP-70) deficiency

Secondary

  • Malnutrition
  • Uncontrolled Diabetes mellitus
  • Chronic uremia
  • Genetic syndromes: trisomy 21
  • Immunomodulatory, immunosuppressive drug therapy: , calcineurin inhibitors, cytotoxic agents
  • Systemic lupus erythematosus
  • Active radiation therapy
  • Bone marrow ablation
  • Infectious diseases: (HIV) infection, Hepatitis

Additional Primary and secondary immunodeficiencies can be found at the following link.

https://www.merckmanuals.com/professional/immunology-allergic-disorders/immunodeficiency-disorders/overview-of-immunodeficiency-disorders

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
72 participants (estimated)

Study arms

  • Placebo comparator
    Placebo (microcrystalline cellulose)

    Placebo capsules by mouth twice daily x 5 days (5 days of placebo microcrystalline cellulose capsules)

    Other: Placebo (microcrystalline cellulose) · Procedure: Wound management

  • Active comparator
    Antibiotic x 1 day

    Amoxicillin-clavulanate 875-125mg capsules by mouth twice daily x 1 day (4 days of placebo capsules) -Penicillin allergy: ciprofloxacin 500mg by mouth twice daily + clindamycin 300mg by mouth three times daily x 1 day

    Drug: Amoxicillin/clavulanate · Drug: Ciprofloxacin · Drug: Clindamycin · Other: Placebo (microcrystalline cellulose) · Procedure: Wound management

  • Active comparator
    Antibiotic x 5 days

    Amoxicillin-clavulanate 875-125mg capsules by mouth twice daily x 5 days (0 days of placebo capsules) -Penicillin allergy: ciprofloxacin 500mg by mouth twice daily + clindamycin 300mg by mouth three times daily x 5 days

    Drug: Amoxicillin/clavulanate · Drug: Ciprofloxacin · Drug: Clindamycin · Procedure: Wound management

Interventions

  • DrugAmoxicillin/clavulanate

    Drug pages: AmoxicillinStudies of AmoxicillinAmoxicillin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Clavulanic AcidStudies of Clavulanic AcidClavulanic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Amoxicillin-clavulanate 875-125mg by mouth twice daily for 1 day or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 1 day

    Also known as: Augmentin; Clavulin; Betacillin; Clavamox

  • Amoxicillin-clavulanate 875-125mg by mouth twice daily for 5 days or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 5 days

    Also known as: Cipro

  • Amoxicillin-clavulanate 875-125mg by mouth twice daily for 5 days or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 5 days

    Also known as: Cleocin

  • OtherPlacebo (microcrystalline cellulose)

    Placebo (microcrystalline cellulose) by mouth twice daily by mouth for 5 days

    Also known as: (C6H10O5)n

  • ProcedureWound management

    Wound management includes hemostasis, copious irrigation, removal of foreign bodies, and excisional debridement of devitalized tissue. If only punctures are present, lancing of the punctures is not typically required unless infection has already developed. Local anesthesia (1% lidocaine hydrogen chloride (HCl) with epinephrine 1:100,000; 200mg/20mL vial) will be used prior to irrigation (30mL of povidone-iodine in 1L of 0.9% sodium chloride (NaCl) solution and/or 118mL of 3% hydrogen peroxide) and debridement. Open wounds will be irrigated and debrided at bedside. Wounds will be covered with soft dressings in place until first follow-up at day 2.

06

What researchers measure

Primary outcomes

  1. Incidence of infection

    To compare the incidence of infection (skin, soft tissue, joint, bone) between each study arm to determine the effect of antibiotic prophylaxis and duration on cat bites to the hand and/or forearm within 30 days. Infections are defined by, The Centers for Disease Control and Prevention National Healthcare Safety Network.

    Time frame: Day 30+/-2

  2. Changes of the incidence of infection

    To compare changes of the incidence of infection (skin, soft tissue, joint, bone) between each study arm and within each study arm to determine the effect of antibiotic prophylaxis and duration on cat bites to the hand and/or forearm at different time points. Infections are defined by the The Centers for Disease Control and Prevention National Healthcare Safety Network.

    Time frame: Day 2; Day 7+/-2; Day 14+/-2; Day 30+/-2

Secondary outcomes

  1. Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) scores

    To compare QuickDASH scores between each study arm to determine the effect of antibiotic prophylaxis and duration on a patient's disability following cat bites to the hand and/or forearm within 30 days. different time points. QuickDASH scores are measured on a scale of 0 to 100 (higher scores indicate increased patient-reported disability).

    Time frame: Day 30+/-2

  2. Changes in Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) scores

    To compare changes in QuickDASH scores between each study arm and within each study arm to determine the effect of antibiotic prophylaxis and duration on a patient's disability following cat bites to the hand and/or forearm at different time points. QuickDASH scores are measured on a scale of 0 to 100 (higher scores indicate increased patient-reported disability).

    Time frame: Day 0, Day 2; Day 7+/-2; Day 14+/-2; Day 30+/-2

  3. HAND Questionnaire (HAND-Q) scores

    To compare HAND-Q scores between each study arm to determine the effect of antibiotic prophylaxis and duration on a patient's quality of life following cat bites to the hand and/or forearm within 30 days. The HAND-Q is composed of independently functioning scales scored separately. To score a scale, the raw scores for the set of items in a scale are added together to produce a total raw score. Items are summed to produce a total scale raw score. A conversion table is used to convert raw scores into a score that ranges from 0 (worst) to 100 (best). The conversion, which linearizes the scores, is based on the findings from the Rasch analysis. Higher scores for HAND-Q scales reflect a better outcome.

    Time frame: Day 30+/-2

  4. Changes in HAND Questionnaire (HAND-Q) scores

    To compare changes in HAND-Q scores between each study arm and within each study arm to determine the effect of antibiotic prophylaxis and duration on a patient's quality of life following cat bites to the hand and/or forearm at different time points. The HAND-Q is composed of independently functioning scales scored separately. To score a scale, the raw scores for the set of items in a scale are added together to produce a total raw score. Items are summed to produce a total scale raw score. A conversion table is used to convert raw scores into a score that ranges from 0 (worst) to 100 (best). The conversion, which linearizes the scores, is based on the findings from the Rasch analysis. Higher scores for HAND-Q scales reflect a better outcome.

    Time frame: Day 0, Day 2; Day 7+/-2; Day 14+/-2; Day 30+/-2

  5. Adverse effects

    To compare adverse effects between each study arm to determine the adverse effects of antibiotic prophylaxis and duration on cat bites to the hand and/or forearm within 30 days.

    Time frame: Day 30+/-2

  6. Changes in adverse effects

    To compare changes in adverse effects between each study arm and within each study arm to determine the adverse effects of antibiotic prophylaxis and duration on cat bites to the hand and/or forearm at different time points.

    Time frame: Day 0, Day 2; Day 7+/-2; Day 14+/-2; Day 30+/-2

Other outcomes

  1. Location of cat bites that result in infection

    To determine if the anatomic location of the cat bite results in the development of the infection within 30 days.

    Time frame: Day 30+/-2

  2. Changes in location of cat bites that result in infection

    To determine if the anatomic location of the cat bite between each study arm and within each study arm results in the development of the infection at different time points.

    Time frame: Day 0, Day 2; Day 7+/-2; Day 14+/-2; Day 30+/-2

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Hudak PL, Amadio PC, Bombardier C. Development of an upper extremity outcome measure: the DASH (disabilities of the arm, shoulder and hand) [corrected]. The Upper Extremity Collaborative Group (UECG). Am J Ind Med. 1996 Jun;29(6):602-8. doi: 10.1002/(SICI)1097-0274(199606)29:63.0.CO;2-L. PubMed 8773720 ↗
  • Sierakowski K, Dean NR, Pusic AL, Cano SJ, Griffin PA, Bain GI, Klassen A, Lalonde D. International multiphase mixed methods study protocol to develop a cross-cultural patient-reported outcome and experience measure for hand conditions (HAND-Q). BMJ Open. 2019 Mar 20;9(3):e025822. doi: 10.1136/bmjopen-2018-025822. PubMed 30898824 ↗
  • Bregman B, Slavinski S. Using emergency department data to conduct dog and animal bite surveillance in New York City, 2003-2006. Public Health Rep. 2012 Mar-Apr;127(2):195-201. doi: 10.1177/003335491212700208. PubMed 22379219 ↗
  • Kwo S, Agarwal JP, Meletiou S. Current treatment of cat bites to the hand and wrist. J Hand Surg Am. 2011 Jan;36(1):152-3. doi: 10.1016/j.jhsa.2009.10.008. Epub 2009 Dec 14. No abstract available. PubMed 20006917 ↗
  • Benson LS, Edwards SL, Schiff AP, Williams CS, Visotsky JL. Dog and cat bites to the hand: treatment and cost assessment. J Hand Surg Am. 2006 Mar;31(3):468-73. doi: 10.1016/j.jhsa.2005.12.011. PubMed 16516744 ↗
  • Kennedy SA, Stoll LE, Lauder AS. Human and other mammalian bite injuries of the hand: evaluation and management. J Am Acad Orthop Surg. 2015 Jan;23(1):47-57. doi: 10.5435/JAAOS-23-01-47. PubMed 25538130 ↗
  • Talan DA, Citron DM, Abrahamian FM, Moran GJ, Goldstein EJ. Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group. N Engl J Med. 1999 Jan 14;340(2):85-92. doi: 10.1056/NEJM199901143400202. PubMed 9887159 ↗
  • Medeiros I, Saconato H. Antibiotic prophylaxis for mammalian bites. Cochrane Database Syst Rev. 2001;(2):CD001738. doi: 10.1002/14651858.CD001738. PubMed 11406003 ↗
  • Lloret A, Egberink H, Addie D, Belak S, Boucraut-Baralon C, Frymus T, Gruffydd-Jones T, Hartmann K, Hosie MJ, Lutz H, Marsilio F, Mostl K, Pennisi MG, Radford AD, Thiry E, Truyen U, Horzinek MC. Pasteurella multocida infection in cats: ABCD guidelines on prevention and management. J Feline Med Surg. 2013 Jul;15(7):570-2. doi: 10.1177/1098612X13489215. PubMed 23813817 ↗
  • Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, Wade JC; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005 Nov 15;41(10):1373-406. doi: 10.1086/497143. Epub 2005 Oct 14. No abstract available. PubMed 16231249 ↗
  • Coburn B, Toye B, Rawte P, Jamieson FB, Farrell DJ, Patel SN. Antimicrobial susceptibilities of clinical isolates of HACEK organisms. Antimicrob Agents Chemother. 2013 Apr;57(4):1989-91. doi: 10.1128/AAC.00111-13. Epub 2013 Feb 12. PubMed 23403420 ↗
  • Beasley H, Borgmann AR, McDonald TO, Belluscio PR. Carbachol in cataract surgery. Arch Ophthalmol. 1968 Jul;80(1):39-41. doi: 10.1001/archopht.1968.00980050041006. No abstract available. PubMed 5660015 ↗
  • Elenbaas RM, McNabney WK, Robinson WA. Evaluation of prophylactic oxacillin in cat bite wounds. Ann Emerg Med. 1984 Mar;13(3):155-7. doi: 10.1016/s0196-0644(84)80604-6. PubMed 6696302 ↗

Individual participant data

Plan to share: No — IPD will not be shared with researchers who have not been approved as study members by the University of Missouri IRB

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Jul 2027, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2023
First posted
May 6, 2023
StartActual
Sep 7, 2023
Primary completionEst.
Jul 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Oct 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05846399
Responsible party
Stephen Colbert (CHIEF OF DIVISION OF PLASTIC SURGERY AND PROFESSOR OF SURGERY, University of Missouri-Columbia) — Principal investigator
First posted
May 6, 2023
Start date
Sep 7, 2023
Primary completion
Jul 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Oct 15, 2025

Study contacts

Stephen H Colbert, MD
Contact
ColbertS@health.missouri.edu
573-882-2277
Kevin M Klifto, DO, PharmD
Contact
kmkdg2@health.missouri.edu
573-882-2277
Kevin M Klifto, DO, PharmD
principal investigator · University of Missouri-Columbia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amoxicillin · Clavulanic Acid · Ciprofloxacin · Clindamycin

Start the discussion